A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

ClinicalTrials.gov ID: NCT07210723

Public ClinicalTrials.gov record NCT07210723. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up

Study identification

NCT ID: NCT07210723
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Kardigan, Inc.; Industry
Enrollment: 332 participants

Conditions and interventions

Conditions

Symptomatic Genetic Dilated Cardiomyopathy

Interventions

danicamtiv Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 12, 2026
Primary completion: Aug 31, 2027
Completion: Dec 31, 2027
Last update posted: Aug 3, 2026

2026 – 2028

United States locations

U.S. sites: 28
U.S. states: 19
U.S. cities: 25

Facility	City	State	ZIP	Site status
University of Alabama Birmingham	Birmingham	Alabama	35233	Recruiting
Cedars Sinai	Los Angeles	California	90048	Recruiting
University of California, Los Angeles (UCLA) - David Geffen School of Medicine	Los Angeles	California	90095	Not yet recruiting
University of California, San Diego (UCSD) - Medical Center	San Diego	California	92037	Recruiting
UCSF	San Francisco	California	94158	Recruiting
Stanford University Medical Center	Stanford	California	94305	Not yet recruiting
MedStar Washington Hospital Center	Washington D.C.	District of Columbia	20010	Recruiting
Mayo Clinic - Jacksonville	Jacksonville	Florida	32224	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
Louisiana State University (LSU) Health Sciences Center	New Orleans	Louisiana	70112	Recruiting
Johns Hopkins Medicine	Baltimore	Maryland	21218	Not yet recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02115	Recruiting
Henry Ford Health System	Detroit	Michigan	48202	Recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Saint Luke's Mid America Heart Institute	Kansas City	Missouri	64111	Not yet recruiting
Washington University in St. Louis	St Louis	Missouri	63110	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68106	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Columbia University Medical Center/ New York Presbyterian Hospital	New York	New York	10027	Not yet recruiting
Duke University Medical Center	Durham	North Carolina	27708	Recruiting
The Lindner Center for Research and Education at The Christ Hospital	Cincinnati	Ohio	45219	Recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	Recruiting
Oregon Health & Science University (OHSU)	Portland	Oregon	97239	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting
Baylor College of Medicine	Houston	Texas	77030	Recruiting
Houston Methodist Hospital	Houston	Texas	77030	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07210723, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 3, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07210723 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →